Breathing New Life into Pulmonary Arterial Hypertension Treatment: Targeting Serotonin Synthesis with an Inhalation Approach.
作者信息
Lee Michael H, Kumar Rahul
机构信息
Zuckerberg San Francisco General Hospital University of California San Francisco San Francisco, California.
出版信息
Am J Respir Cell Mol Biol. 2025 Aug;73(2):168-169. doi: 10.1165/rcmb.2025-0040ED.
Abstract
摘要
相似文献
1
Breathing New Life into Pulmonary Arterial Hypertension Treatment: Targeting Serotonin Synthesis with an Inhalation Approach.
Am J Respir Cell Mol Biol. 2025 Aug;73(2):168-169. doi: 10.1165/rcmb.2025-0040ED.
2
Inhalation of the Novel Tryptophan Hydroxylase 1 Inhibitor TPT-004 Alleviates Pulmonary Arterial Hypertension.
Am J Respir Cell Mol Biol. 2025 Aug;73(2):288-298. doi: 10.1165/rcmb.2024-0365OC.
3
Effect of an Overnight Stay at 2,500 Meters on Nocturnal Hypoxemia and Sleep-disordered Breathing in Patients with Pulmonary Vascular Disease: A Randomized Clinical Trial.
Ann Am Thorac Soc. 2025 Jul;22(7):1053-1061. doi: 10.1513/AnnalsATS.202412-1279OC.
4
Successful upfront combination therapy against pulmonary arterial hypertension associated with unilateral absence of the pulmonary artery: a case report.
Eur Heart J Case Rep. 2025 Jul 10;9(7):ytaf328. doi: 10.1093/ehjcr/ytaf328. eCollection 2025 Jul.
5
Digital Tracking of Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Observational Study (VENTASTEP).
J Med Internet Res. 2021 Oct 8;23(10):e25163. doi: 10.2196/25163.
6
Macitentan and Tadalafil Combination Therapy in Patients with Pulmonary Arterial Hypertension and Cardiovascular Comorbidities: Real-World Evidence from OPUS and OrPHeUS.
Adv Ther. 2025 May 19. doi: 10.1007/s12325-025-03180-0.
7
Pharmacokinetics and Lung Deposition After Administration of Inhaled Mosliciguat (BAY 1237592): Results from Randomized Phase I Studies in Healthy Men.
Clin Pharmacokinet. 2025 May 22. doi: 10.1007/s40262-025-01503-6.
8
Role of the serotonin transporter in pulmonary arterial hypertension.
Expert Rev Clin Pharmacol. 2008 Nov;1(6):749-57. doi: 10.1586/17512433.1.6.749.
9
Comparison of the efficacy of inhaled versus infused milrinone in the management of persistent pulmonary hypertension of the newborn in resource-limited settings: A randomized clinical trial.
Pediatr Pulmonol. 2023 Jul;58(7):2132-2139. doi: 10.1002/ppul.26451. Epub 2023 May 3.
10
Haemodynamic effects of ketanserin either alone or with oxygen in COPD patients with secondary pulmonary hypertension.
Monaldi Arch Chest Dis. 1997 Oct;52(5):429-33.
本文引用的文献
1
Inhalation of the Novel Tryptophan Hydroxylase 1 Inhibitor TPT-004 Alleviates Pulmonary Arterial Hypertension.
Am J Respir Cell Mol Biol. 2025 Aug;73(2):288-298. doi: 10.1165/rcmb.2024-0365OC.
2
Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trial.
Lancet Respir Med. 2024 Nov;12(11):865-876. doi: 10.1016/S2213-2600(24)00226-1. Epub 2024 Sep 19.
3
Serotonin and Pulmonary Hypertension; Sex and Drugs and ROCK and Rho.
Compr Physiol. 2022 Aug 29;12(4):4103-4118. doi: 10.1002/cphy.c220004.
4
Endothelial indoleamine 2,3-dioxygenase protects against development of pulmonary hypertension.
Am J Respir Crit Care Med. 2013 Aug 15;188(4):482-91. doi: 10.1164/rccm.201304-0700OC.
5
Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression.
Am J Respir Crit Care Med. 2013 Jan 1;187(1):78-89. doi: 10.1164/rccm.201206-1028OC. Epub 2012 Oct 18.
6
In vivo effects of a combined 5-HT1B receptor/SERT antagonist in experimental pulmonary hypertension.
Cardiovasc Res. 2010 Feb 1;85(3):593-603. doi: 10.1093/cvr/cvp306. Epub 2009 Sep 7.
7
Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice.
Circulation. 2008 Jun 3;117(22):2928-37. doi: 10.1161/CIRCULATIONAHA.108.767558. Epub 2008 May 27.
8
Tryptophan hydroxylase 1 knockout and tryptophan hydroxylase 2 polymorphism: effects on hypoxic pulmonary hypertension in mice.
Am J Physiol Lung Cell Mol Physiol. 2007 Oct;293(4):L1045-52. doi: 10.1152/ajplung.00082.2007. Epub 2007 Aug 3.
9
Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension.
Am J Respir Crit Care Med. 2003 Aug 15;168(4):487-93. doi: 10.1164/rccm.200210-1212OC. Epub 2003 May 28.
10
Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension.
FASEB J. 2001 Feb;15(2):427-38. doi: 10.1096/fj.00-0343com.
Zotero 插件